1. Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis
   Kwang-Beom Lee et al, 2018, Journal of Gynecologic Oncology CrossRef
2. Perioperative treatments for stage IB–IIB uterine cervical cancer
   Muneaki Shimada et al, 2020, Japanese Journal of Clinical Oncology CrossRef
3. Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)
   Maki Matoda et al, 2018, Gynecologic Oncology CrossRef
4. Vaginal carcinoma in a young woman who underwent fertility‐sparing treatment involving chemotherapy and conservative surgery
   Yasushi Mabuchi et al, 2015, Journal of Obstetrics and Gynaecology Research CrossRef
5. Multi‐institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOG‐G1201)
   Taisuke Mori et al, 2019, Journal of Obstetrics and Gynaecology Research CrossRef
6. Successful neoadjuvant chemotherapy for large cell neuroendocrine carcinoma of the cervix: A case report
   Makiko Omori et al, 2014, Gynecologic Oncology Case Reports CrossRef
7. Propensity Score Analysis of Radical Hysterectomy Versus Definitive Chemoradiation for FIGO Stage IIB Cervical Cancer
   Natsuo Tomita et al, 2018, International Journal of Gynecologic Cancer CrossRef
8. Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy
   Eriko Takatori et al, 2013, Journal of Obstetrics and Gynaecology Research CrossRef
9. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan
   Yasuhiko Nakamura et al, 2015, Journal of Obstetrics and Gynaecology Research CrossRef
10. Nedaplatin Salvage Chemotherapy for Cervical Cancer
    Wu-Ju Li et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
11. Rethinking the significance of surgery for uterine cervical cancer
    Muneaki Shimada et al, 2022, Journal of Obstetrics and Gynaecology Research CrossRef
12. Cervical cancer treatment in Haiti: A vertically-integrated model for low-resource settings
    Vincent DeGennaro et al, 2019, Gynecologic Oncology Reports CrossRef
13. Impact ofUGT1A1genotype upon toxicities of combination with low-dose irinotecan plus platinum
    Masashi Takano et al, 2016, Asia-Pacific Journal of Clinical Oncology CrossRef
14. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study
    Zhijun Yang et al, 2016, Gynecologic Oncology CrossRef
15. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions
    Yuki Kawarada et al, 2017, International Journal of Clinical Oncology CrossRef
16. Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib
    Y. Wang et al, 2013, Clinical and Translational Oncology CrossRef
17. Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
    Naoki Horikawa et al, 2015, BMC Cancer CrossRef
18. Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
    Hisham A Abou-Taleb et al, 2016, Journal of International Medical Research CrossRef
19. Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: Long-term results
    G. Ferrandina et al, 2013, Gynecologic Oncology CrossRef
20. UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
    Hideki Matsuoka et al, 2020, BMC Cancer CrossRef
21. Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity
    Mizue Teramoto et al, 2014, Medical Molecular Morphology CrossRef
22. Impact of Histopathological Risk Factors on the Treatment of Stage IB-IIB Uterine Cervical Cancer
    Muneaki Shimada et al, 2020, The Tohoku Journal of Experimental Medicine CrossRef
23. Effects of neoadjuvant chemotherapy on patients with primary vaginal squamous cell carcinoma
    Yuchao Diao et al, 2017, Molecular and Clinical Oncology CrossRef
24. Treatment for Patients with Adenocarcinoma of Uterine Cervix
    Muneaki Shimada et al, 2015, International Manual of Oncology Practice CrossRef
25. Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy
    Eriko Takatori et al, 2015, International Journal of Clinical Oncology CrossRef